Celgene Corp. (CELG)

98.95
NASDAQ : Health Technology
Prev Close 98.67
Day Low/High 98.45 / 99.33
52 Wk Low/High 58.59 / 99.36
Avg Volume 3.80M
Exchange NASDAQ
Shares Outstanding 708.74M
Market Cap 69.93B
EPS 5.70
P/E Ratio 13.51
Div & Yield N.A. (N.A)
Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups In Adults With Relapsing Multiple Sclerosis

Analysis Showed Oral Ozanimod Reduced Brain Volume Loss Across All Age Subgroups In Adults With Relapsing Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced the results of a post-hoc analysis of data from the Phase 3 RADIANCE™ Part B trial showing that ozanimod reduced cortical grey matter volume loss versus first-line treatment, Avonex ® (interferon beta-1a),...

What to Watch Out For: Cramer's 'Mad Money' Recap (Thursday 5/2/19)

What to Watch Out For: Cramer's 'Mad Money' Recap (Thursday 5/2/19)

Jim Cramer says that although a sell-off can breed a buying opportunity, investors need to worry about sky-high IPOs and other signs of froth.

Shake It All Out

Nothing’s wrong with a market correction – the Russell 2000 even outperformed – but keep your eyes on the declining McClellan Summation Index.

Real Money Post-Industrial Average Leaves Major Indices in the Dust

Real Money Post-Industrial Average Leaves Major Indices in the Dust

RMPIA outperformed once gain during April.

Celgene Corporation And Bluebird Bio Announce Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Multiple Myeloma Published In New England Journal Of Medicine

Celgene Corporation And Bluebird Bio Announce Results From Ongoing Multicenter Phase 1 Study Of Bb2121 Anti-BCMA CAR T Cell Therapy In Patients With Multiple Myeloma Published In New England Journal Of Medicine

Celgene Corporation (Nasdaq: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the New England Journal of Medicine (NEJM) has published interim results from CRB-401, the ongoing phase 1 study of bb2121, the companies' lead investigational...

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Marketing Authorization Application To The European Medicines Agency (EMA) For MDS And Beta-Thalassemia

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Marketing Authorization Application To The European Medicines Agency (EMA) For MDS And Beta-Thalassemia

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for luspatercept for the treatment of adult patients...

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Jim Cramer: My Bet's on the 'Ladies' in This Year's Draft

Analyzing this year's stock draft contest and individual stock-picking vs. indexing.

Celgene Reports First Quarter 2019 Operating And Financial Results

Celgene Reports First Quarter 2019 Operating And Financial Results

Celgene Corporation (NASDAQ:CELG) reported net product sales of $4,024 million for the first quarter of 2019, a 14 percent increase from the same period in 2018.

Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval

Bristol-Myers Tops Q1 Earnings Estimate After Winning Celgene Takeover Approval

Bristol-Myers Squibb posted stronger than-expected first quarter earnings Thursday, and boosted one of its key profit forecast, after seeing off an activist challenge to its $74 billion takeover of cancer specialist Celgene earlier this month.

Stocks Edge Lower as Growth Concerns Resurface, Offsetting Solid US Earnings

Stocks Edge Lower as Growth Concerns Resurface, Offsetting Solid US Earnings

Global stocks pared gains Thursday, as weakening data and dovish central bank actions added to concerns over the pace of world growth and offset the bullish tenor from last night's after-the-bell earnings on Wall Street.

Bristol-Myers Squibb Company Announces Commencement Of Exchange Offers And Consent Solicitations For Celgene Notes

Bristol-Myers Squibb Company Announces Commencement Of Exchange Offers And Consent Solicitations For Celgene Notes

Bristol-Myers Squibb Company (NYSE:BMY) ("Bristol-Myers Squibb) announced today the commencement, in connection with its previously announced acquisition of Celgene Corporation (NASDAQ:CELG) ("Celgene") , of an exchange offer for any and all outstanding...

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Bullish Start to Earnings: Cramer's 'Mad Money' Recap (Friday 4/12/19)

Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Bristol-Myers Squibb Shareholders Approve Celgene Tie-Up

Three quarters of Bristol-Myers Squibb shareholders vote to approve the deal with Celgene, paving the way for the largest pharmaceutical takeover in history.

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb

Celgene Stockholders Approve Proposed Acquisition By Bristol-Myers Squibb

Celgene Corporation (NASDAQ: CELG) today announced that its stockholders have voted to approve the company's proposed combination with Bristol-Myers Squibb Company (NYSE: BMY).

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA

Celgene Corporation And Acceleron Pharma Announce Submission Of Luspatercept Biologics License Application To U.S. FDA

Celgene Corporation (NASDAQ: CELG) and Acceleron Pharma Inc. (NASDAQ: XLRN) today announced that Celgene has submitted a Biologics License Application (BLA) for luspatercept, an erythroid maturation agent, for the treatment of adult patients with very low...

Predicting the Future: Cramer's 'Mad Money' Recap (Monday 4/1/19)

Predicting the Future: Cramer's 'Mad Money' Recap (Monday 4/1/19)

How can stocks rally with money coming out so swiftly? Jim Cramer says to take a look at the 5 best performing stocks in the Dow for the first quarter.

Williams-Sonoma, Fortive, Western Digital: 'Mad Money' Lightning Round

Williams-Sonoma, Fortive, Western Digital: 'Mad Money' Lightning Round

Jim Cramer takes a look at Williams-Sonoma, Fortive, Western Digital, Goodyear Tire & Rubber, Celgene, Welltower, Box and Twitter.

Keep Your Eye on the Oncology Sector Among Biotech Stocks

Keep Your Eye on the Oncology Sector Among Biotech Stocks

The myriad names in oncology have been the hottest area for acquisitions along with gene therapy.

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Bristol-Myers Gets ISS Support for Celgene Takeover; Starboard Drops Opposition

Celgene surges Friday after an influential shareholder advisory group recommend investors vote in favor of the cancer drug specialist's takeover by Bristol-Myers Squibb Co. while a key activist dropped its opposition to the $74 billion deal.

Celgene Settles U.S. REVLIMID® Patent Litigation With Alvogen

Celgene Settles U.S. REVLIMID® Patent Litigation With Alvogen

Celgene Corporation (NASDAQ:CELG) and Lotus Pharmaceutical Co., Ltd.

Celgene Receives CHMP Positive Opinions For Both REVLIMID® (lenalidomide) And IMNOVID® (pomalidomide)-Based Triplet Combination Regimens For Patients With Multiple Myeloma

Celgene Receives CHMP Positive Opinions For Both REVLIMID® (lenalidomide) And IMNOVID® (pomalidomide)-Based Triplet Combination Regimens For Patients With Multiple Myeloma

Celgene Corporation (NASDAQ:CELG), today announced that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted positive opinions for two triplet regimens based on Celgene's proprietary IMiD ® medications,...

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Stock Picking Comeback: Cramer's 'Mad Money' Recap (Thursday 3/28/19)

Lots of IPOs and innovation will reward investors who do their homework, Jim Cramer says.

Future Brightens for 2 Small Biotech Stocks

Future Brightens for 2 Small Biotech Stocks

The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.

Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal

Bristol-Myers Gets FTC Request for More Information on $74 Billion Celgene Deal

Bristol-Myers Squibb says Tuesday the Federal Trade Commission has requested information related to its planned $74 billion takeover of cancer drug company Celgene.

Bristol-Myers Squibb, Xilinx, Nieslen: 'Mad Money' Lightning Round

Bristol-Myers Squibb, Xilinx, Nieslen: 'Mad Money' Lightning Round

Jim Cramer takes a look at Bristol-Myers Squibb, Xilinx, Nieslen, Realty Income, W&T Offshore and more.

Celgene Submits Application To FDA For Ozanimod For The Treatment Of Relapsing Forms Of Multiple Sclerosis

Celgene Submits Application To FDA For Ozanimod For The Treatment Of Relapsing Forms Of Multiple Sclerosis

Celgene Corporation (NASDAQ:CELG) today announced that the Company has submitted a New Drug Application to the U.

Bristol-Myers Squibb Board Of Directors Sends Letter To Shareholders Highlighting The Compelling Strategic And Financial Rationale Of The Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Board Of Directors Sends Letter To Shareholders Highlighting The Compelling Strategic And Financial Rationale Of The Celgene Transaction; Company Provides Additional Investor Materials

Bristol-Myers Squibb Company's (NYSE:BMY) Board of Directors today sent an open letter to the Company's shareholders regarding the previously announced definitive merger agreement with Celgene Corporation (NASDAQ:CELG).

Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

Bristol-Myers Pushes Celgene Deal, Starboard Hits Back, in $74B Takeover Spat

Bristol-Myers Squibb trades blows with activist investor Starboard Value Tuesday as the pair issues competing presentations linked to the pharmaceutical group's planned $74 billion takeover of cancer drug specialist Celgene.

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Why Shareholders Should Vote for Bristol-Myers Celgene Deal: Jim Cramer

Jim Cramer thinks that Bristol-Myer's deal with Celgene is a positive thing, despite Starboard's resistance.

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Jim Cramer: Tilray's Earnings, Bristol-Myers and Celgene and Elon Musk

Bristol-Myers, Tilray, and Elon Musk are some of the top headlines in business news Tuesday. Here's what Jim Cramer's watching.

TheStreet Quant Rating: C+ (Hold)